Chris C.
“Getting the opportunity to put my own stamp on shaping the future supply chain that will bring life saving medicine to patients.“ — Chris C.
Bob T.
“I was eager to join Allogene for the people and the science. I get to work with intelligent, driven colleagues while studying the “crazy” science of treating recipient patients with…
Alice C.
“To find satisfaction in striving towards a collective purpose, to face the challenges of scientific innovation for improving (and saving) lives of fellow human beings.“ — Alice C.
@AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO
Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about…
@AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO
Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about…
Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO
Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about…
- Go to the previous page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- Go to the next page